Cited by

• Comparison of three different anti-Xa assays in major orthopedic surgery patients treated with direct oral anticoagulant.

  Ikejiri M, Wada H, Tone S, Wakabayashi H, Hasegawa M, Matsumoto T, Fujimoto N, Yamada N, Ito M, Nakatani K, Sudo A. Ikejiri M, et al. Thromb J. 2017 Oct 12;15:27. doi: 10.1186/s12959-017-0150-4. eCollection 2017. Thromb J. 2017. PMID: 29046616 Free PMC article.
• Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery.

  Lundkvist J, Bergqvist D, Jönsson B. Lundkvist J, et al. Eur J Health Econ. 2007 Dec;8(4):313-23. doi: 10.1007/s10198-006-0017-2. Epub 2007 Jan 16. Eur J Health Econ. 2007. PMID: 17225129
• Ambulatory Portable Pneumatic Compression Device as Part of a Multimodal Aspirin-Based Approach in Prevention of Venous Thromboembolism in Outpatient Total Knee Arthroplasty.

  Crawford DA, Andrews RL, Morris MJ, Hurst JM, Lombardi AV Jr, Berend KR. Crawford DA, et al. Arthroplast Today. 2020 Jun 16;6(3):378-380. doi: 10.1016/j.artd.2020.05.007. eCollection 2020 Sep. Arthroplast Today. 2020. PMID: 32577481 Free PMC article.
• Monitoring for anti-Xa activity for prophylactic administration of Fondaparinux in patients with artificial joint replacement.

  Yoshida K, Wada H, Hasegawa M, Wakabayashi H, Ando H, Oshima S, Matsumoto T, Shimokariya Y, Noma K, Yamada N, Uchida A, Nobori T, Sudo A. Yoshida K, et al. Int J Hematol. 2011 Oct;94(4):355-360. doi: 10.1007/s12185-011-0933-5. Epub 2011 Sep 22. Int J Hematol. 2011. PMID: 21935756 Clinical Trial.
• Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery.

  Sullivan SD, Kahn SR, Davidson BL, Borris L, Bossuyt P, Raskob G. Sullivan SD, et al. Pharmacoeconomics. 2003;21(7):477-96. doi: 10.2165/00019053-200321070-00003. Pharmacoeconomics. 2003. PMID: 12696988 Review.